myosin subfragments

Preferred Label : myosin subfragments;

MeSH definition : Parts of the myosin molecule resulting from cleavage by proteolytic enzymes (PAPAIN; TRYPSIN; or CHYMOTRYPSIN) at well-localized regions. Study of these isolated fragments helps to delineate the functional roles of different parts of myosin. Two of the most common subfragments are myosin S-1 and myosin S-2. S-1 contains the heads of the heavy chains plus the light chains and S-2 contains part of the double-stranded, alpha-helical, heavy chain tail (myosin rod).;

MeSH synonym : subfragments, myosin;

MeSH hyponym : heavy meromyosin Subfragment-2; light meromyosin; actoheavy meromyosin; heavy meromyosin; meromyosin subfragments; heavy meromyosin Subfragment-1; Heavy Meromyosin Subfragment 2; Meromyosin Subfragment-2, Heavy; Subfragment-2, Heavy Meromyosin; Myosin Subfragment-2; Myosin Subfragment 2; Subfragment-2, Myosin; Myosin S-2; Myosin S 2; Meromyosin, Light; Myosin Rod; Meromyosin, Heavy; H-Meromyosin; H Meromyosin; Meromyosin, Actoheavy; Heavy Meromyosin Subfragment 1; Meromyosin Subfragment-1, Heavy; Subfragment-1, Heavy Meromyosin; Myosin Subfragment-1; Myosin Subfragment 1; Subfragment-1, Myosin; ATPase, Actin-S1; Actin-S1 ATPase; Myosin S-1; Myosin S 1; Actin S1 ATPase; ATPase, Actin S1; Actomyosin Subfragment 1 ATPase; Subfragments, Meromyosin;

Related MeSH term : actomyosin subfragments; Subfragments, Actomyosin;

Is substance : O;

Details

Origin ID

D015879;

UMLS CUI

C0027117;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Altretamine [NCIt concept]
- Hidden Markov Model [NCIt concept]
Record concept(s)
- actoheavy meromyosin [MeSH concept]
- actomyosin subfragments [MeSH concept]
- heavy meromyosin [MeSH concept]
- heavy meromyosin Subfragment-1 [MeSH concept]
- heavy meromyosin Subfragment-2 [MeSH concept]
- light meromyosin [MeSH concept]
- meromyosin subfragments [MeSH concept]
- myosin subfragments [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients